Articles related to CME

Participants should be better able to discuss anti-VEGF therapy outcomes in patients with moderate-severe and severe nonproliferative diabetic retinopathy after taking part in this educational activity with Drs. Susan Bressler, Mark Dunbar, and Ruth Weinstock, and understand the importance of prompt referral and early diagnosis to reduce or even prevent the vision-threatening complications of diabetes.

Acquired/congenital bone marrow failure, thalassemia/hemoglobinopathies, transfusion medicine, new therapies (pharmacology), infections of the immunocompromised, hematologic malignancies (acute/chronic leukemias; myeloma/lymphomas), thoracic oncology (head/neck/lung/thyroid), and many other practice improvement areas are covered in this CME activity worth up to 41.25 credits. The video curriculum starts at $1,795 in price.

Approved? Not-approved? What is “tentative approval?” Clinical trial data on this novel “once nightly” sodium oxibate showed the drug to be acceptable for narcolepsy. But legal issues are holding up the FDA approval process.

Medical oncologists, pulmonologists, pathologists, oncology nurses, pharmacists, and other oncology HCPs who treat patients with lung cancer should be better able to describe ideal evidence-based treatment selection and sequencing recommendations for the use of immuno-oncologic therapy in patients with early-stage NSCLC and evaluate clinical trial data of emerging immunotherapy-based agents in the treatment after completing this three-chapter, 0.50-credit CME activity.

Innovative and creative Risky Business events emphasize risk management, patient safety, and safety awareness. To enable all of their colleagues to work in a safer environment, they continuously “raise the bar” by exchanging safety ideas and experiences across industries. The integration of experiences from speakers representing a wide range of non-healthcare businesses into a coherent narrative and actionable results is a crucial component of Risky Business. In this two-hour video webinar taking place on Thursday, January 12 from 10:00 AM to noon , the panelists will talk about a wide range of topics, including systemic problems, workforce implications, community needs, and what industry experts are doing to address the situation. To address challenges of capacity and resource strain, they will examine cutting-edge digital technology and government and healthcare system collaboration.

Doctors and other healthcare professionals should be better able to describe the current role of immuno-oncology (IO) in patients with hepatocellular carcinoma (HCC) and evaluate how new information on novel IO strategies may alter the approach to therapy in HCC after completing this four-chapter CME activity.